IMA Clinical Research’s parent IMA Group has acquired Accelemed Research Institute for an undisclosed price, continuing the clinical trial site company’s expansion march across the U.S.
The latest deal is the eighth acquisition by IMA Group's clinical research division since 2018. With the purchase of Accelemed, based in Austin, Texas, IMA picks up its second clinical research site in the Lone Star State and fifth in the southwest.
IMA now has 17 independent research sites nationally, including in Arizona, New York, Nevada and Florida, along with five embedded within physician offices in Louisiana and North Carolina, the company said in an April 11 press release.
Accelemed’s trial sites are focused on cardiometabolic and gastrointestinal diseases such as nonalcoholic steatohepatitis, obesity, high cholesterol and diabetes.
“We continually look for ways to ensure clinical trials are accessible and meaningful to the people who will most benefit from promising therapies and medications,” Mark Weinberger, IMA Group’s president and CEO, said in the release. “Accelemed’s focus on chronic, debilitating diseases and patient diversity complement the core capabilities of IMA’s therapeutic offerings and our commitment to expanded patient access.”
In January, IMA bought Clinical Trials of America for an undisclosed sum, increasing the company’s presence in the U.S. southeast.